Use of Tamoxifen in Systemic Mastocytosis

Completed

Conditions studied: Systemic Mastocytosis

In brief

In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic agent, to improve quality of life, biochemical parameters, and bone marrow involvement in systemic mastocytosis patients having 1) up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard "non-cytotoxic" medications regardless of the percentage bone marrow involvement by mastocytosis. The dose of Tamoxifen will be 40 mg/day and the duration of treatment will be for one year. Patients currently taking interferon alfa, imatinib mesylate, or cladribine will be excluded until these medications have been stopped.

Key facts

Study ID

NCT01334996

Run by

Mayo Clinic

People needed

1

Starts

2005-02-01

Expected to finish

2019-08-28

Last updated by the study team

2020-04-10

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Systemic Mastocytosis

You may not qualify if…

• Current treatment with Imatinib mesylate, cladribine or interferon alpha.

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.